[Screening of undifferentiated carcinoma of the nasopharynx].
Screening for nasopharyngeal carcinoma (NPC) is being conducted as a quasi-experiment in the south east of the People's Republic of China using serological markers of the Epstein-Barr virus. Several studies are available but the efficacy of screening in terms of impact on mortality from NPC has not yet been demonstrated. Valid experimental studies should be carried out before implementing population-based screening programmes in Chinese or North African populations which are known for their high risk of NPC.
Sasco
A J
AJ
Centre international de recherche sur le cancer, Lyon, France.
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002277:Carcinoma / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D002681:China / Q000453:epidemiology; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D011237:Predictive Value of Tests; D012307:Risk Factors; D016036:Seroepidemiologic Studies
D014408:Biomarkers, Tumor; D007070:Immunoglobulin A
Dépistage des carcinomes indifférenciés du nasopharynx.